Ali Ghodsizad

Ali Ghodsizad

Auto-generated profile, based on publicly available information

Ali Ghodsizad

University of Miami

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2018 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
AGApril A. Grant
April A. Grant
VHValerie J. Hart
Valerie J. Hart
ELEdward B. Lineen
Edward B. Lineen
ABAmit Badiye
Amit Badiye
PBPatricia M. Byers
Patricia M. Byers
AGAli Ghodsizad
Ali Ghodsizad

29 March 2020 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
Ilija DjordjevicIlija Djordjevic
Ilija Djordjevic
KEKaveh Eghbalzadeh
Kaveh Eghbalzadeh
ASAnton Sabashnikov
Anton Sabashnikov
ADAntje‐Christin Deppe
Antje‐Christin Deppe
EKElmar Kuhn
Elmar Kuhn
TWThorsten Wahlers
Thorsten Wahlers
Objectives Central or peripheral venoarterial extracorporeal membrane oxygenation (va ECMO) is widely used in postcardiotomy cardiogenic shock (PCS). Available data suggest controversial results for both types. Our aim was to investigate PCS patients treated with either peripheral (pECMO) or central ECMO (cECMO) concerning their outcome. Methods Between April 2006 and October 2016, 156 consecutive patients with va ECMO therapy due to PCS were identified and included in this retrospective analysis. Patients were divided into cECMO and pECMO groups. Statistical analysis of risk factors concerning 30‐day mortality of the mentioned patient cohort was performed using IBM SPSS Statistics. Results Fifty‐six patients received cECMO and 100 patients were treated with pECMO due to PCS. In the group of cECMO peripheral vascular disease was significantly more present (cECMO 19 [34%] vs pECMO 14 [14%]; P < .01). On‐site ECMO complications occurred significantly more frequent in patients treated with cECMO (cECMO 44 [79%] vs pECMO 54 [54%] g/dL; P < 0.01). More often cECMO patients required a second look operation due to mediastinal bleeding (cECMO 52 [93%] vs pECMO 61 [61%] g/dL; P < .01). Thirty‐day mortality was comparable with nearly 70% in both cohorts (cECMO 39 [70%] vs pECMO 69 [69%]; P = .93). Conclusion Patients supported by cECMO or pECMO due to refractory PCS did not show significant differences in 30‐day mortality, despite a lower incidence of on‐site ECMO complications and re‐exploration in pECMO patients. PCS itself is associated with high mortality and peripheral cannulation might help to save resources compared with central cannulation.

24 July 2018 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
AGApril A. Grant
April A. Grant
VHValerie J. Hart
Valerie J. Hart
ELEdward B. Lineen
Edward B. Lineen
CLCynthia Lai
Cynthia Lai
EGEnrique Ginzburg
Enrique Ginzburg
AGAli Ghodsizad
Ali Ghodsizad

15 June 2013 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
AGAli Ghodsizad
Ali Ghodsizad
ARArjang Ruhparwar
Arjang Ruhparwar
VBViktor Bordel
Viktor Bordel
EMEbrahim Mirsaidighazi
Ebrahim Mirsaidighazi
HKHans Michael Klein
Hans Michael Klein
AEAly El‐Banayosy
Aly El‐Banayosy
Summary: Introduction: Cardiovascular disease is a major cause of death worldwide. Different medical and surgical therapeutic options are well established, but a significant number of patients are not amenable to standard therapeutic options. Cell‐based therapies after clinical application have shown different results in recent years. Here, we are giving a comprehensive overview on major available clinical data regarding cell therapy.Background: Cell‐based therapies and tissue engineering provide new promising platforms to develop upcoming therapeutic options. Initial clinical trials were able to generate promising results. A variety of different stem cell types have been used for the clinical application. Different adult cardiac stem cells and progenitor cells, including mesenchymal, CD34+ and CD133+ autologous human bone marrow–derived stem cells (BMCs), human myoblasts, and peripheral blood–derived stem and progenitor cells (PBSCs) have been used for the therapy for end‐stage heart failure. Future experiments will show the importance of novel cell populations and clarify the mechanism causing cell therapy–mediated observed effects.Conclusion: Several clinical trials have reported on sole therapy, as well as combined application of autologous adult stem cells with conventional revascularization. The reported promising findings encourage further research in the field of the translational research.

5 November 2019 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
AGApril A. Grant
April A. Grant
ELEdward B. Lineen
Edward B. Lineen
AKAlan Klima
Alan Klima
RVRodrigo Vianna
Rodrigo Vianna
MLMatthias Loebe
Matthias Loebe
AGAli Ghodsizad
Ali Ghodsizad

1 September 2014 in ASAIO Journal
Verified
Journal Article
Closed access
AGAli Ghodsizad
Ali Ghodsizad
VBViktor Bordel
Viktor Bordel
HWHerrman Wiedensohler
Herrman Wiedensohler
AEAli Elbanayosy
Ali Elbanayosy
MKMichael Martin Koerner
Michael Martin Koerner
ARArjang Ruhparwar
Arjang Ruhparwar
Application of somatic stem cells for growth, proliferation, and differentiation in a three-dimensional pattern is an important aspect in tissue engineering. Here, we report on our bioreactor, which we applied for magnetically guided recellularization of nitinol-stented valve. Human-derived unrestricted somatic stem cells were cultured in medium in our pulsatile dynamic bioreactor for 4–6 days. Stented valves were prepared by decellularization of porcine pericardium and construction of stented tissue-engineered valves (n = 8). A magnetic field was created around the bioreactor to prevent the loss of cells. In the control group, no magnetic device was used (n = 4). Morphological characterization was assessed by immunohistochemical staining of paraffin sections and electron microscopy. The bioreactor enabled the preservation of physiologic culture conditions with aerobic cell metabolism and physiological pH values. Histological analysis showed homogeneous seeding of the pericardium with progenitor cells in the recellularized samples, whereas no cell seeding could be observed in the nonmagnetic group. Our magnetically guided multifunctional bioreactor allows for an efficient three-dimensional culturing of somatic stem cells on decellularized organ-specific matrix.